When was Kallyope founded?

Kallyope was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is Kallyope located?

Kallyope is headquartered in New York City, United States.

How many employees does Kallyope have?

As of Jun 30, 2026, the latest employee count at Kallyope is 64.

Is Kallyope a funded company?

Kallyope is a funded company, having raised a total of $479M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 10, 2015.

When was the latest funding round of Kallyope?

Kallyope's latest funding was a $***** Grant (prize money) round on May 10, 2023, with participation from 1 investor.

Where does Kallyope rank among its competitors?

Kallyope ranks 4th amongst 99 active competitors, of which 36 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was mbiomics, which secured $14.1M in Apr, 2026.

Who are the top competitors of Kallyope?

Kallyope's top competitors include MaaT Pharma, Trace Genomics and Biotia. Among them, mbiomics secured the most recent funding round in April, 2026.

Kallyope - 2026 Company Profile, Team, Funding & Competitors

Kallyope is a series D company based in New York City (United States), founded in 2014 by Tom Maniatis, Charles Zuker and Richard Axel. It operates as a Discovering novel therapeutics for neurological and metabolic diseases. Kallyope has raised $479M in funding from investors like Lux Capital, The Column Group and Illumina Ventures. The company has 99 active competitors, including 36 funded and 18 that have exited. Its top competitors include companies like MaaT Pharma, Trace Genomics and Biotia.

Company Details

Discovering novel therapeutics for neurological and metabolic diseases. The company focuses on addressing significant health challenges by developing effective and well-tolerated agents. Utilizing the Klarity Platform, scientists investigate medicines targeting metabolism, including type 2 diabetes and obesity, and neurological disorders like migraine and pain. The company pursues innovative approaches to medicine discovery, integrating technologies for differentiated therapeutic development. With a team of scientists and drug developers, the company fosters a culture of innovation and collaboration to advance human health. The company operates in the pharmaceutical and biotechnology sectors, focusing on research and development to create solutions for unmet medical needs. The company's work has a direct social impact by aiming to improve the lives of patients and families affected by these diseases.

Key Metrics

Founded Year

2014

Location

New York City, United States

Stage

Series D

Total Funding

$479M in 6 rounds

Latest Funding Round

Grant (prize money), May 10, 2023, $*****

Investors

Lux Capital & 22 more

Ranked

4^th among 99 active competitors

Employee Count

64 as on Jun 30, 2026

Similar Companies

MaaT Pharma & 127 more

View Kallyope's full profile

Kallyope is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Kallyope Inc CIN: 47-2537283 , United States, Active	Nov 06, 2014	-	84 (As on Dec 31, 2021)	-

Kallyope has raised a total funding of $479M over 6 rounds. Its first funding round was on Dec 10, 2015. Its latest funding round was a Grant (prize money) round on May 10, 2023 for $*****. 1 investor participated in its latest round. Kallyope has 22 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Kallyope:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 10, 2023	4181018	Grant (prize money)	1187652	7317888	8152529	5122440
Feb 15, 2022	5000944	Series D	5932163	7532947	3480992	Lux Capital & 13 more
Mar 26, 2020	8338236	Series C	8689193	5039155	Illumina Ventures & 1 more	The Column Group & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Kallyope's funding rounds and investors

The founders of Kallyope are Tom Maniatis, Charles Zuker and Richard Axel.

Here are the details of Kallyope's key team members:

Tom Maniatis: Co-Founder of Kallyope. They serve on the board of 1 company.
Charles Zuker: Co-Founder of Kallyope.
Richard Axel: Co-Founder of Kallyope.

Kallyope's Board of Directors

Kallyope's board has 9 active members. Terry McGuire, Michael O'Donnell, Kenneth Clark, Tom Maniatis, Adam Goulburn, Joshua Wolfe, William Rieflin, Nancy Thornberry and Tim Kutzkey are independent board members.

Here is the list of Kallyope's board of directors:

Name	Type	Representing	Status	Duration
Terry McGuire	Independent board member	-	Current	10y 8m
znwsu{q	Independent board member	-	Current	7y 2m
dchpa{y	Independent board member	-	Current	7y 7m
jmbcbuc	Independent board member	-	Current	4y 8m
jzbdojb	Independent board member	-	Current	7y 7m
urcrlq{	Independent board member	-	Current	2y 6m
hjujvtt	Independent board member	-	Current	3y 4m
uflmwwj	Independent board member	-	Current	4y 9m
kbhxytr	Independent board member	-	Current	4y 5m

View details of Kallyope's Founder profiles and Board Members

Kallyope's employee count trend

Kallyope has 64 employees as of Jun 26. Here is Kallyope's employee count trend over the years:

Uncover Kallyope's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kallyope include MaaT Pharma, Trace Genomics and Biotia. Here is the list of Top 10 competitors of Kallyope, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Bpifrance, Symbiosis & 11 others	65/100
2nd	Trace Genomics 2015, Ames (United States), Series B	Provider of soil intelligence technology for sustainable agriculture and food	$53.6M	Rabo Investments, THRIVE & 19 others	60/100
3rd	Biotia 2016, Brooklyn (United States), Series A	Provider of sequencing-based solutions for hospitals	$10.4M	OCA Ventures, Leawood Venture Capital & 16 others	59/100
4th	Kallyope 2014, New York City (United States), Series D	Discovering novel therapeutics for neurological and metabolic diseases	$479M	Acks, Mubadala & 21 others	59/100
5th	Finch Therapeutics 2004, Somerville (United States), Public	Developer of microbiome-based therapies by using human-first discovery platform	$184M	Willett Advisors, Avenir Growth Capital & 19 others	57/100
6th	Metagen Therapeutics 2020, Tokyo (Japan), Series B	Developer of therapeutics based on human gut microbiome	$36.8M	FTI, JIC Venture Growth Investments & 21 others	56/100
7th	OptiBiotix Health 2012, York (United Kingdom), Public	Developer of microbial strains for the treatment of human metabolic diseases	-	Seneca EIS Portfolio Fund, Enterprise Ventures ... & 2 others	55/100
8th	Solarea Bio 2017, Cambridge (United States), Series B	Innovating microbial solutions for human health, focusing on aging well	$37.2M	S2G Investments, Bold Capital Partners & 8 others	55/100
9th	mbiomics 2020, Munich (Germany), Series A	Provider of a genomic-based platform for microbiome-based therapeutics development	$35.2M	MIG Fonds, Bayern Kapital & 1 others	55/100
10th	BioCorteX 2021, London (United Kingdom), Seed	Developer of human-microbiome platform for drug development	$5M	Sofinnova Partners, Hoxton Ventures & 1 others	53/100